The clinical course was as baffling as it was prolonged. Earlier biopsies had revealed pigmented fungal elements, including thick-walled budding spores, but cultures repeatedly failed to identify a culprit. Multiple rounds of intravenous and oral antifungal therapy produced only partial and temporary improvement. One clue proved especially telling: the infection waxed and waned with the seasons, worsening in winter and partially receding in summer. That pattern would later make biological sense, because laboratory testing showed that the fungus is psychrotolerant, growing best at 26 degrees Celsius, poorly above 30 degrees, and not at all at 37 or 40 degrees. In other words, the organism thrives at temperatures closer to a cool room than to human core body temperature, which may explain why the infection stayed confined to the cooler surfaces of the skin for more than three decades.

To crack the case, researchers at the Institute of Dermatology of the Chinese Academy of Medical Sciences in Nanjing and their collaborators turned to molecular tools. Because the isolate refused to produce conidia, the spore-like reproductive structures that mycologists normally use for identification, on any of six different culture media or under any lighting condition, the team sequenced four genetic barcodes: the internal transcribed spacer region, the large subunit ribosomal RNA gene, translation elongation factor 1-alpha, and RNA polymerase II’s second largest subunit. Sequence comparisons and phylogenetic analysis placed the clinical isolate firmly within the Brunneofusispora hyalina clade, matching the ex-type strain of a species described only in 2021. The isolate has been designated strain CAMS-CCPM-D 05816 and its sequences deposited in GenBank, giving future clinicians a reference point for recognizing similar infections.

The patient’s own genome held the other half of the explanation. Whole-exome sequencing revealed two heterozygous variants in the CARD9 gene, which encodes an adaptor protein central to antifungal immunity. One was a frameshift variant classified as pathogenic, the other a synonymous change of uncertain significance. CARD9 deficiency is a well-established inborn error of immunity that impairs interleukin-17-mediated responses, the arm of the immune system that guards skin and mucosa against fungi, and it predisposes carriers to invasive infections by both yeasts and melanized molds. Previous research has shown that CARD9 mutations are linked to subcutaneous phaeohyphomycosis and deficits in Th17 cell function, and a striking concentration of such infections has been documented in East Asia, where a founder mutation is prevalent and where environmental exposure to diverse dematiaceous fungi may add further risk.

Whole-genome sequencing of the fungus itself added a layer of technical depth to the story. The assembly, built from Illumina reads at roughly 125-fold coverage, spans about 44.5 megabases with a GC content of 48.76 percent, values consistent with other black yeasts and their relatives. Gene prediction yielded 13,777 genes, and functional annotation revealed substantial metabolic versatility, with secondary metabolite biosynthesis, carbohydrate transport, and amino acid metabolism among the most heavily represented functional categories. Most intriguingly, a search against the Pathogen-Host Interactions database identified 395 homologs of known virulence or pathogenicity proteins, but more than seventy percent of the top matches came from plant-pathogenic fungi such as Magnaporthe oryzae and Fusarium graminearum, with only a small share corresponding to human pathogens. The authors caution that sequence homology alone does not confirm virulence function, since many matches involve deeply conserved housekeeping proteins, but the pattern suggests B. hyalina lacks specialized weapons for attacking humans and instead exploits weaknesses in host defenses.

Determining which drugs could actually inhibit this unusual organism posed its own methodological challenge. Because the fungus would not sporulate and grew slowly, the standard CLSI M38 broth microdilution protocol, which depends on a standardized conidial inoculum, could not be applied directly. The team instead developed a modified agar dilution test using hyphal fragments and adapted a broth dilution method, testing six antifungal agents in triplicate with quality-control strains. The results were encouraging for the newer agents: voriconazole, posaconazole, and itraconazole all showed low minimum inhibitory concentrations, and terbinafine was the most potent of all at 0.25 to 0.5 micrograms per milliliter. Fluconazole, by contrast, required a concentration of 128 micrograms per milliliter to inhibit growth, marking the isolate as effectively resistant. Amphotericin B produced a notable discrepancy, with the agar method suggesting an MIC above 16 micrograms per milliliter while the broth method yielded 2, a gap of more than three twofold dilution steps that underscores how testing methodology can reshape interpretation for slow-growing molds.

To test whether the fungus’s modest virulence truly depends on a permissive host, the researchers built an infection model in mice. Wild-type C57BL/6 mice injected subcutaneously in the footpad developed a sharp inflammatory swelling in the first week, but the inflammation subsided rapidly, and by week eight the difference between infected and control paws had shrunk to just 0.04 millimeters, indicating resolution. CARD9 knockout mice told a different story: their paws remained chronically swollen between roughly 1.08 and 1.42 millimeters throughout eight weeks of observation, with no mortality but no spontaneous recovery either. This mirrors the human case in miniature, a persistent, localized, granulomatous infection that never turns lethal but never lets go, and it contrasts with more virulent dematiaceous fungi such as Fonsecaea pedrosoi, which can kill CARD9-deficient mice.

The treatment experiments were sobering. Starting three weeks after infection, knockout mice received oral voriconazole and terbinafine at doses converted from standard adult regimens using body-surface-area calculations. Within the first week of therapy, paw swelling fell more than fourfold relative to untreated knockout controls, and fungal burden in the infected tissue dropped by more than half. Yet after six weeks of combination therapy, residual swelling persisted, and histopathology with PAS and H&E staining still revealed granulomatous inflammation and viable fungal hyphae in the skin. The drug combination reduced the disease but could not eradicate the pathogen, a finding that echoes the patient’s own experience of relapse after a full year of posaconazole monotherapy. She is currently maintained on posaconazole plus terbinafine with good control, but the fungus was re-isolated once before, after she stopped the earlier treatment.

Taken together, the study reframes how a rarely seen environmental saprotroph becomes a clinical problem. The fungus carries a plant-associated genetic toolkit, tolerates only cool temperatures, and shows no obvious capacity for deep tissue invasion or systemic spread; what it needs is an opening, which in this case came in the form of a heterozygous CARD9 variant that blunted the IL-17-dependent defenses of the skin. The authors argue that where host immunity is the weak link, antifungal drugs alone may be insufficient, and they point to two complementary strategies worth exploring: immune restoration to rebuild the defective antifungal response, and local hyperthermia, which becomes conceptually attractive given that exposure to 40 degrees Celsius irreversibly killed the organism in culture, although they emphasize that such approaches remain untested hypotheses rather than clinical recommendations. For now, the case stands as both a taxonomy milestone and a cautionary one, expanding the roster of dematiaceous fungi capable of causing phaeohyphomycosis and reminding clinicians that in patients with recurrent or atypical dark skin lesions that resist conventional therapy, the answer may lie not only in the culture dish but also in the patient’s own DNA.

Subject of Research: Opportunistic cutaneous phaeohyphomycosis caused by the newly described environmental fungus Brunneofusispora hyalina in a patient with a heterozygous CARD9 variant

Article Title: Persistent cutaneous phaeohyphomycosis caused by Brunneofusispora hyalina in a patient with a heterozygous CARD9 variant: the opportunistic potential of a newly described environmental fungus

Article References: Mei, H., Li, D., Jing, D., Wang, X., Deng, S., Daly, P., Zheng, H., She, X., Fu, M., & Liu, W. (2026). Persistent cutaneous phaeohyphomycosis caused by Brunneofusispora hyalina in a patient with a heterozygous CARD9 variant: the opportunistic potential of a newly described environmental fungus. Frontiers in Fungal Biology, 7, Article 1938341. https://doi.org/10.3389/ffunb.2026.1938341

Image Credits: AI Generated

DOI: 10.3389/ffunb.2026.1938341

Keywords: Brunneofusispora hyalina, phaeohyphomycosis, CARD9, dematiaceous fungi, antifungal susceptibility, whole-genome sequencing, murine infection model, medical mycology, immunodeficiency, triazoles, terbinafine, Pleosporales

Inborn errors of immunity, abbreviated IEI, are a group of more than 400 genetically determined disorders in which components of the immune system are missing, malfunctioning, or misdirected. The spectrum ranges from well-known conditions such as Common Variable Immunodeficiency, in which the body fails to produce adequate levels of protective immunoglobulin G antibodies, to rare monogenic defects affecting single signaling pathways. Because the immune defect is written into the genome, these are lifelong conditions. Patients typically experience recurrent, severe, or unusual infections, and many require regular immunoglobulin replacement therapy delivered intravenously or subcutaneously. What has received far less attention is the psychological dimension of living with such a vulnerability, and the new study was designed to address exactly that gap.

The research team, led by Luca J. Wolff and Thea Thiele of the Department of Rheumatology and Immunology at Hannover Medical School, together with psychiatrist Kai G. Kahl, recruited 143 adults from their clinic. The cohort included 88 women and 55 men with a mean age of 45.4 years, spanning ages 21 to 85. Each participant completed two widely validated screening instruments: the Patient Health Questionnaire-9, or PHQ-9, which quantifies depressive symptoms across nine diagnostic criteria, and the Generalized Anxiety Disorder-7, or GAD-7, which does the same for anxiety. Scores of 10 or higher on either instrument are conventionally interpreted as indicating at least moderate symptoms that warrant clinical attention. The researchers also collected routine clinical data, including the underlying diagnosis, documented psychiatric comorbidities, susceptibility to infections, and whether patients deliberately self-isolated because of infection-related concerns.

The headline numbers reveal a population under measurable strain. The median PHQ-9 score in the cohort was 5, with an interquartile range of 8, and the median GAD-7 score was 5, with an interquartile range of 7. On both scales, a score of 5 marks the threshold for mild symptoms, meaning that the typical patient in this study was already reporting noticeable, if subclinical, levels of depressive and anxious symptomatology. More concerning was the distribution above the clinical threshold. Among the 140 patients with valid PHQ-9 scores, eleven had scores of at least 10 despite having no documented psychiatric diagnosis. Taken together, roughly a quarter of patients with clinically relevant symptoms, 26 percent, had never been diagnosed or treated for a mental health condition.

The most statistically robust finding concerned self-isolation. Patients who reported isolating themselves because of concerns about infection had markedly higher symptom scores than those who did not. The association was quantified using Spearman’s rank correlation, a non-parametric measure of monotonic association suitable for ordinal questionnaire data. For depression, the correlation coefficient was 0.52, and for anxiety it was 0.48, both statistically significant at p less than 0.001. In behavioral science, correlations of this magnitude are considered moderate to strong, and they suggest that the degree of voluntary social withdrawal tracks closely with psychological distress. The authors emphasize that the cross-sectional design cannot determine whether isolation drives the symptoms, whether depressed and anxious patients withdraw more, or whether both are fed by a common cause such as fatigue, pain, or the cumulative burden of chronic illness.

That ambiguity is important, because the study also measured fatigue, pain, and quality of life using visual analogue scales, simple instruments in which patients rate their subjective experience on a continuous line. Chronic fatigue and pain are well-documented companions of immune deficiency, arising from repeated infections, inflammatory activity, and the physical toll of therapy schedules. Both are also established risk factors for depression in virtually every chronic disease studied, from rheumatoid arthritis to multiple sclerosis. In patients with IEI, these somatic symptoms may create a vicious circle: feeling exhausted and unwell discourages social engagement, social withdrawal deepens low mood, and low mood further reduces the motivation to maintain contact with friends, family, and even medical services.

The pandemic made this dynamic vividly familiar to the general population. Healthy people experienced only a compressed version of what immune-deficient patients navigate permanently: the calculation before every meeting, the weighing of a dinner party against a respiratory infection, the slow erosion of social confidence. Research from the pandemic years consistently showed that prolonged isolation increased rates of depression and anxiety even in people with no underlying medical vulnerability. The Hannover findings extend that lesson to a group for whom isolation is not a temporary public health measure but a rational, ongoing response to a genuine medical threat. The psychological cost, the study suggests, is real and quantifiable, even when the isolation is medically sensible.

Why did so many symptomatic patients go undiagnosed? The authors point to the structure of specialist care. Adults with inborn errors of immunity are typically managed by immunologists and rheumatologists whose consultations focus on infection history, antibody levels, and replacement therapy dosing. Mental health screening is not routinely embedded in these visits, and patients themselves may not volunteer psychological complaints when their medical agenda is dominated by physical symptoms. The PHQ-9 and GAD-7 take only a few minutes to complete, and the study’s results argue that administering them at regular intervals in immunology clinics could surface a substantial hidden burden. Eleven patients with PHQ-9 scores of 10 or above and no psychiatric diagnosis is a small absolute number, but in a cohort of only 143 it represents a meaningful fraction, and the 26 percent treatment gap among symptomatic patients suggests the problem scales beyond this single center.

The study’s conclusions carry practical implications for how care for these patients is organized. The authors call for greater awareness of mental health issues and for multidisciplinary care models in which immunologists, primary care physicians, and mental health professionals collaborate. Such models are already standard in oncology and increasingly in chronic inflammatory diseases, where the interplay between immune function and mood is well recognized. Interestingly, the biology may run in both directions: chronic psychological stress alters cortisol and inflammatory signaling, and in patients whose immune regulation is already genetically compromised, the clinical consequences of that interaction remain an open research question. The Hannover team did not test mechanistic hypotheses, but their data provide the epidemiological foundation for such work.

For patients and families, the message is that the emotional weight of living with an immune defect deserves explicit attention, not quiet endurance. Feeling persistently down, tense, or exhausted is not an inevitable part of having a rare disease that must simply be accepted; it is a treatable component of the illness experience. For clinicians, the message is that a two-questionnaire screen and a conversation about social isolation could identify patients who are suffering invisibly. And for the broader public, the study is a reminder of a lesson the pandemic taught and then faded: that protecting the body from infection by withdrawing from the world exacts a measurable toll on the mind, and that toll deserves the same seriousness as any laboratory value on a patient’s chart.

Subject of Research: Depression and anxiety in patients with inborn errors of immunity and their association with infection-related self-isolation

Article Title: Frequency of depression and anxiety in patients with inborn errors of immunity: a cross-sectional study

Article References: Wolff, L. J., Witte, T., Kahl, K. G., Meinecke, A., Ahrenstorf, G., Sogkas, G., Hillmer, S., & Thiele, T. (2026). Frequency of depression and anxiety in patients with inborn errors of immunity: a cross-sectional study. BMC Psychiatry, 26(1), Article 721. https://doi.org/10.1186/s12888-026-08654-1

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08654-1

Keywords: inborn errors of immunity, depression, anxiety, self-isolation, PHQ-9, GAD-7, common variable immunodeficiency, mental health, quality of life, immunodeficiency, cross-sectional study, multidisciplinary care

Chronic lymphocytic leukaemia, or CLL, is a malignancy characterised by the progressive accumulation of monoclonal lymphocytes bearing a distinctive immunophenotype — cells that are CD5-positive, CD19-positive, CD20-dim, CD23-positive and express dim surface immunoglobulin — in the peripheral blood, bone marrow and lymphoid tissues. Unlike many other chronic lymphoproliferative disorders, CLL is defined as much by its immunological consequences as by its malignant ones. Patients frequently present with immune disturbances and recurrent infections, a feature that makes the disease particularly dangerous in the era of a novel respiratory virus. The leukaemic cells crowd out functional immune components, and the humoral arm of the immune system is often left strikingly weakened.

The patient in this report had been diagnosed with CLL four years before she presented with fever. For the two years preceding her COVID-19 illness, she had been receiving ibrutinib, a targeted Bruton tyrosine kinase inhibitor used as maintenance therapy. While ibrutinib has transformed the management of CLL, it adds another layer of immunosuppression to a disease already defined by immune dysfunction. When her symptoms began, a computed tomography scan of the chest revealed a pattern of ground-glass opacities, the hazy radiological signature familiar to clinicians throughout the pandemic, and RT-PCR testing confirmed SARS-CoV-2 infection.

What followed was a clinical course that departed sharply from the expected trajectory. Two weeks after the patient had clinically recovered, repeat RT-PCR testing remained positive. Twenty-eight days later, she returned to medical attention with fever and weakness. On admission, her clinicians discontinued ibrutinib, a common practice for patients with COVID-19 intended to minimise potential drug-related complications and reduce the burden of immunosuppression. She was treated with dexamethasone to manage inflammation and remdesivir as antiviral therapy, both standard interventions for hospitalised COVID-19 patients aimed at curbing viral replication and blunting the cytokine-driven tissue damage that characterises severe disease.

Despite this conventional therapeutic arsenal, the virus would not retreat. Serial RT-PCR tests performed on nasopharyngeal aspirates continued to detect the SARS-CoV-2 genome, with positivity persisting up to 127 days after symptom onset. Throughout this period, the patient remained under quarantine and home observation. Laboratory findings captured the depth of her illness: a white blood cell count of 50 × 10⁹ per litre with 88 percent lymphocytes, reflecting the leukaemic burden; a C-reactive protein level of 200 mg/L and an erythrocyte sedimentation rate of 119 mm/hour, markers of vigorous systemic inflammation; and elevated liver enzymes, with alanine aminotransferase at 87 U/L and aspartate aminotransferase at 75 U/L. Eventually, on day 127, her oxygen saturation declined, and she died in the intensive care unit.

The authors of the report attribute this extraordinary duration of viral shedding to the profound immunodeficiency associated with CLL, further compromised by ongoing chemotherapy and ibrutinib therapy. Central to this vulnerability is hypogammaglobulinemia, a hallmark of CLL in which levels of protective antibodies — IgG, IgA and IgM — fall below the thresholds needed for effective host defence. These immunoglobulins are crucial for neutralising SARS-CoV-2 and preventing its dissemination within the body. When the humoral immune system cannot mount a competent antibody response against the virus, viral replication proceeds unchecked, and shedding continues for months rather than weeks. The patient’s failure to seroconvert, noted by the authors, aligns with a growing body of evidence showing that CLL patients mount suboptimal antibody responses to SARS-CoV-2 infection.

This immunological failure helps explain a broader and troubling pattern. Early reports from China indicated that individuals with cancer are more susceptible to SARS-CoV-2, although initial data on the prevalence and features of COVID-19 across different cancers, including CLL, were limited. Subsequent studies have shown that patients with CLL are more likely to experience severe COVID-19, with higher rates of hospitalisation, intensive care unit admission and mortality compared to the general population. Advanced age compounds the risk, and this patient’s 69 years, combined with ongoing chemotherapy, placed her in a particularly precarious position. Prolonged viral shedding has been documented in other immunocompromised individuals as well, but the distinguishing feature of this case, according to the authors, is the demonstration that early cessation of targeted therapy combined with standard antiviral and corticosteroid administration was entirely insufficient to halt continuous viral replication, ultimately leading to fatal hypoxemia by day 127.

The case also raises uncomfortable questions about the limits of standard COVID-19 therapy in immunocompromised hosts. Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA-dependent RNA polymerase, and dexamethasone, a corticosteroid that dampens the inflammatory cascade, were developed and validated largely in populations with intact immune systems. In a patient who cannot generate neutralising antibodies, the report suggests, these treatments may not suffice to achieve viral clearance. The authors point instead to monoclonal antibodies such as casirivimab and imdevimab, which have shown promise in facilitating rapid viral clearance in CLL patients grappling with persistent infections. By supplying exogenous neutralising antibodies, such therapies can in principle substitute for the humoral response the patient’s own body cannot mount, offering a potential therapeutic avenue where conventional regimens fall short.

Supportive measures aimed at correcting the underlying antibody deficiency may hold similar promise. The authors highlight intravenous immunoglobulin infusions, which replenish circulating IgG and can provide passive immunity against a broad range of pathogens, as an intervention that may improve outcomes among CLL patients infected with SARS-CoV-2. Cited literature includes a reported case of long-lasting SARS-CoV-2 infection with post-COVID-19 chronic interstitial pneumonia in a CLL patient treated successfully with intravenous immunoglobulin, suggesting that addressing hypogammaglobulinemia directly can alter the course of otherwise intractable infections. Robust monitoring of viral shedding in such patients is also emphasised, both to guide therapy and to minimise potential transmission risks from prolonged carriers — a public health consideration, since immunocompromised individuals who harbour replicating virus for months are also environments in which new variants can emerge.

The report’s authors conclude that the prevalence, clinical characteristics and outcomes of COVID-19 in CLL patients have yet to be fully established, and that preliminary data from large patient series remain valuable for understanding and managing these cases. Their central message is a call for tailored strategies that go beyond remdesivir and dexamethasone, particularly given the high mortality linked to comorbidities in this population. For clinicians, the case is a reminder that a positive RT-PCR test in an immunocompromised patient is not merely a lingering molecular echo of a resolved infection; it can reflect genuinely ongoing viral replication. For virologists, it is a vivid demonstration of the delicate equilibrium between host immunity and viral persistence — an equilibrium that, when the immune system fails, can stretch a two-week illness into a 127-day ordeal with a fatal end.

Subject of Research: Prolonged SARS-CoV-2 RNA shedding in a chronic lymphocytic leukaemia patient with impaired antibody responses

Article Title: Persistent SARS‐CoV‐2 RNA Positivity in a Chronic Lymphocytic Leukaemia Patient for 127 Days After Disease Onset: A Case Report

Article References: Khamseh, F., Moghtader‐Mojdehi, A.-H., Nemati, Z., & Haghighi, M. (2026). Persistent SARS ‐ CoV ‐2 RNA Positivity in a Chronic Lymphocytic Leukaemia Patient for 127 Days After Disease Onset: A Case Report. Respirology Case Reports, 14(10), Article e70767. https://doi.org/10.1002/rcr2.70767

Image Credits: AI Generated

DOI: 10.1002/rcr2.70767

Keywords: SARS-CoV-2, chronic lymphocytic leukaemia, viral shedding, immunodeficiency, hypogammaglobulinemia, ibrutinib, remdesivir, dexamethasone, RT-PCR, monoclonal antibodies, COVID-19, case report

The research team followed 156 adults who developed invasive pneumococcal disease and required hospital care in Region Västra Götaland, Sweden, between 2018 and 2023. The median age of the patients was 70 years, a demographic in which both pneumococcal disease and blood malignancies become progressively more common. To determine whether the severe infection was merely bad luck or a signal of hidden vulnerability, the researchers performed detailed immunological workups. They measured antibody levels to detect deficiencies in humoral immunity, and they tested for the presence of M protein, a monoclonal immunoglobulin that serves as a well-established risk marker for blood cancer. A control group of 64 individuals, matched for age and sex but without invasive pneumococcal disease, provided a baseline for comparison.

The results were striking. Among the patients with invasive pneumococcal disease, one in four had M protein detectable in their blood. Monoclonal gammopathy of this kind can occur in established blood cancers, but it is also found in precursor states, conditions that do not yet meet the criteria for malignancy but can, in some patients, progress toward cancer over time. The examinations prompted by the study led to seven patients receiving a diagnosis of blood cancer, while another twelve were diagnosed with a precursor condition that may, in some cases, evolve into malignancy. In a group of just over 150 patients admitted for a severe bacterial infection, that represents a meaningful yield of previously silent disease.

The immune assessments also uncovered antibody deficiencies. Eight patients in the pneumococcal disease group were found to have immunodeficiency, and in seven of them, clinicians were able to start preventive treatment aimed at protecting against future severe infections. Such treatments can include replacement immunoglobulin therapy and tailored vaccination strategies, interventions that can substantially reduce the risk of recurrent invasive disease. By contrast, these abnormalities were considerably less common in the matched control group, reinforcing the idea that invasive pneumococcal infection is not randomly distributed but clusters in people whose immune surveillance is compromised.

The biological logic behind these findings is straightforward once the mechanics of pneumococcal immunity are considered. Streptococcus pneumoniae is an encapsulated bacterium, and its polysaccharide capsule is the principal target of protective antibodies. Clearance of the organism depends heavily on opsonization, the process by which antibodies coat the bacterium and mark it for destruction by phagocytic cells. People with low antibody levels, whether from a primary immunodeficiency or from the antibody-producing B-cell disorders that underlie many blood cancers, are therefore structurally less able to contain the bacterium when it colonizes the respiratory tract. What would be a mild or localized infection in an immunocompetent adult can become a systemic, hospital-requiring illness in someone whose humoral immunity is impaired.

M protein, the marker at the center of the study, is a monoclonal immunoglobulin produced by a single expanded clone of plasma cells or B cells. Its presence in the blood is the hallmark of a spectrum of disorders ranging from the benign-appearing monoclonal gammopathy of undetermined significance to smoldering and symptomatic myeloma. Because monoclonal gammopathies are common in older populations and often remain asymptomatic for years, most are discovered incidentally or not at all. The Gothenburg study suggests that severe pneumococcal disease may function as a clinical flag: when an older adult presents with invasive infection, the probability of finding an underlying monoclonal disorder is high enough that targeted testing could be worthwhile.

Currently, according to the researchers, these tests are not routinely performed after a severe pneumococcal infection. Tor Härnqvist, a doctoral student at the University of Gothenburg and an infectious disease physician at NU Hospital Group, and one of the lead authors of the study, points to the consequence of that gap. “Currently, these tests are not routinely performed after a severe pneumococcal infection. As a result, we may miss patients with undiagnosed blood cancer or immunodeficiency and therefore missing the opportunity to initiate treatment,” he says. The missed opportunity cuts in two directions: blood cancers such as myeloma are generally more treatable when identified before organ damage accumulates, and immunodeficiencies can be mitigated with preventive measures before the next invasive infection occurs.

The study carries implications for vaccination policy as well. Karin Bergman, a doctoral student in the same research group and an infectious disease physician at Södra Älvsborg Hospital, examined how the pneumococcal bacteria causing severe disease have shifted since the pneumococcal conjugate vaccine was introduced into the Swedish childhood vaccination program. Her analysis, part of a doctoral thesis she will soon defend at the University of Gothenburg, shows that the bacterial serotypes covered by the childhood vaccine have decreased sharply in circulation, but they have largely been replaced by other serotypes against which the childhood vaccine offers no protection. This serotype replacement is a well-documented ecological consequence of conjugate vaccination: eliminating vaccine-targeted strains from nasopharyngeal carriage opens ecological space for non-vaccine strains to colonize and spread.

Crucially, the serotypes now driving invasive disease in adults disproportionately affect older adults and individuals with underlying conditions, particularly cancer and compromised immune systems. This creates an uncomfortable alignment: the very populations most vulnerable to severe pneumococcal infection are those most likely to harbor undiagnosed blood cancer or antibody deficiency, and the circulating bacterial strains are precisely those that exploit gaps in adult immunity. “The results show that recommendations on pneumococcal vaccines for adults need to take into account which vaccines are used in children and which bacterial serotypes subsequently circulate in the community,” says Bergman. In other words, adult immunization strategy cannot be designed in isolation from the pediatric program, because the two are epidemiologically linked through the shifting serotype landscape.

Taken together, the findings support a concrete change in clinical practice. The researchers argue that screening for M proteins and antibody levels should be considered in adults who experience invasive pneumococcal disease, since the infection can reveal previously undiagnosed blood cancer and immunodeficiency. Such screening would involve relatively simple blood tests: quantitative measurement of serum immunoglobulins to identify antibody deficiencies, and protein electrophoresis or equivalent methods to detect monoclonal immunoglobulins. For a patient population that is already hospitalized and undergoing extensive workup, the incremental burden would be modest, while the potential benefit, catching a blood cancer or an immune deficiency that would otherwise remain hidden until it caused further harm, could be substantial. As populations age and serotype replacement continues to reshape pneumococcal epidemiology, the severe pneumonia that lands an older adult in the hospital may increasingly deserve to be read not only as an infection, but as a message from the immune system itself.

Subject of Research: Invasive pneumococcal disease as a marker of undiagnosed blood cancer and immunodeficiency in adults

Article Title: Pneumonia can reveal undiagnosed blood cancer

Article References: Pneumonia can reveal undiagnosed blood cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: pneumococcal disease, pneumonia, blood cancer, M protein, immunodeficiency, monoclonal gammopathy, Streptococcus pneumoniae, antibody deficiency, pneumococcal vaccine, serotype replacement, University of Gothenburg, Scientific Reports